Cyclopharm Ltd (CYC) – Strategy, SWOT and Corporate Finance Report

Cyclopharm Ltd (CYC) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Cyclopharm Ltd (Cyclopharm) is a radiopharmaceutical company that manufactures medical and healthcare equipment and components in nuclear medicine. The company’s products include Technegas, an ultra-fine dispersion of technetium-labelled carbon used for the detection of pulmonary embolism. The company is evaluating Technegas in new indications including chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary hypertension, lung volume reduction and asthma. Cyclopharm operates a joint venture, Macquarie Medical Imaging, which provides diagnostic imaging services such as magnetic resonance imaging (MRI), computed tomography (CT), breast imaging, X-ray, ultrasound, dual-energy X-ray absorptiometry (DEXA) and positron emission tomography (PET) scanning. It harnesses its Ultralute technology, which extends the life of Molybdenum-99 generators. It operates in Asia Pacific, Canada, Latin America, Europe and Germany. Cyclopharm is headquartered in New South Wales, Australia.

Scope

• Detailed information on Cyclopharm Ltd required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Cyclopharm Ltd in the form of a SWOT analysis

• An in-depth view of the business model of Cyclopharm Ltd including a breakdown and examination of key business segments

• News about Cyclopharm Ltd, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Cyclopharm Ltd and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Cyclopharm Ltd as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Cyclopharm Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Telix Pharmaceuticals Ltd

PETNET Solutions Cleveland LLC

Optiscan Imaging Ltd

Kent Hospital

China Wah Yan Healthcare Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Cyclopharm Ltd - Key Facts

Cyclopharm Ltd - Key Employees

Cyclopharm Ltd - Key Employee Biographies

Cyclopharm Ltd - Major Products and Services

Cyclopharm Ltd - History

Cyclopharm Ltd - Company Statement

Cyclopharm Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 – Company Analysis

Company Overview

Cyclopharm Ltd - Business Description

Business Segment: Molecular Imaging

Overview

Performance

Business Segment: Technegas

Overview

Performance

Geographical Segment: Asia Pacific

Performance

Geographical Segment: Canada

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Other

Performance

R&D Overview

Cyclopharm Ltd - Corporate Strategy

Cyclopharm Ltd - SWOT Analysis

SWOT Analysis - Overview

Cyclopharm Ltd - Strengths

Cyclopharm Ltd - Weaknesses

Cyclopharm Ltd - Opportunities

Cyclopharm Ltd - Threats

Cyclopharm Ltd - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Cyclopharm Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 09, 2023: Cyclopharm confirms USFDA scheduled inspection date

Nov 29, 2022: Cyclopharm receives A$1.64 million AusIndustry research and development refund

Jul 04, 2022: Cyclopharm : 1H 2022 business update – Record revenues

Feb 24, 2022: Cyclopharm provides business update – FDA progress, record revenues and positive clinical trial results

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Cyclopharm Ltd, Key Facts

Cyclopharm Ltd, Key Employees

Cyclopharm Ltd, Key Employee Biographies

Cyclopharm Ltd, Major Products and Services

Cyclopharm Ltd, History

Cyclopharm Ltd, Subsidiaries

Cyclopharm Ltd, Joint Venture

Cyclopharm Ltd, Key Competitors

Cyclopharm Ltd, Ratios based on current share price

Cyclopharm Ltd, Annual Ratios

Cyclopharm Ltd, Annual Ratios (Cont…1)

Cyclopharm Ltd, Annual Ratios (Cont…2)

Cyclopharm Ltd, Interim Ratios

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Cyclopharm Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Cyclopharm Ltd, Performance Chart (2018 – 2022)

Cyclopharm Ltd, Ratio Charts

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports